Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Mar;44(3):794-7.
doi: 10.1128/AAC.44.3.794-797.2000.

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

L M Demeter  1 , R W Shafer, P M Meehan, J Holden-Wiltse, M A Fischl, W W Freimuth, M F Para, R C Reichman
Affiliations
Clinical Trial

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

L M Demeter et al. Antimicrob Agents Chemother. 2000 Mar.

Abstract

The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
HIV-1 reverse transcriptase mutations in isolates from patients in ACTG 260. The pie chart represents the frequency of RT mutations in week 8 isolates. Isolates from a total of 30 patients were analyzed. None of the mutations represented here was present in the corresponding baseline isolates.
See this image and copyright information in PMC

References

    1. Byrnes V W, Sardana V V, Schleif W A, Condra J H, Waterbury J A, Wolfgang J A, Long W J, Schneider C L, Schlabach A J, Wolanski B S, et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother. 1993;37:1576–1579. - PMC - PubMed
    1. de Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med Res Rev. 1996;16:125–157. - PubMed
    1. Demeter L M, Meehan P M, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman R C. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:136–144. - PubMed
    1. Dueweke T J, Poppe S M, Romero D L, Swaney S M, So A G, Downey K M, Althaus I W, Reusser F, Busso M, Resnick L, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 1993;37:1127–1131. - PMC - PubMed
    1. Dueweke T J, Pushkarskaya T, Poppe S M, Swaney S M, Zhao J Q, Chen I S, Stevenson M, Tarpley W G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA. 1993;90:4713–4717. - PMC - PubMed

Publication types

MeSH terms

Associated data